Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Terence Flynn maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $20 to $22.
Morgan Stanley analyst Terence Flynn maintains Arcus Biosciences (NYSE:RCUS) with a Equal-Weight and raises the price target from $20 to $22.